ArticleMagyar onkologia2025
[The effect of PSMA PET/CT performed in primary staging on the clinical decision].
Article in Magyar onkologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimOur study aimed to conduct a retrospective statistical analysis of 18F-JK-PSMA-7 PET/CT results in high-risk prostate cancer patients as part of primary staging, to assess how these results influenced the original treatment plan.
methodsThe study included high-risk prostate adenocarcinoma patients, localized by conventional imaging, who underwent PSMA PET/CT as part of primary staging between 03/01/2020 and 03/01/2022.
resultsPSMA PET/CT confirmed distant metastasis in 20 out of 74 patients. Among them, 7 received local treatment due to oligometastatic disease. The remaining 13 patients had distant lymph node metastasis (1 patient), bone metastasis only (2 patients), or both (10 patients). Based on PSMA PET/CT results, these 13 patients received systemic treatment instead of local therapy. No significant statistical correlation was found between PSA levels, ISUP score, and distant metastasis verification.
conclusionBroader use of PSMA PET/CT in primary staging of high-risk prostate cancer patients could allow for more precise, personalized therapy in the future.
Indexed as
Identifiers
40643456PMC12255501What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.